BioMarin posts first $1 billion quarter, sets VOXZOGO PDUFA date for hypochondroplasiaNov 2Quarterly updateBiomarin Pharmaceutical Incvosoritide
Zevra reports Q2 2026 results as MIPLYFFA revenue grows and EU review continuesAug 5Quarterly updatearimoclomolZevra Therapeutics, Inc.
Zevra Therapeutics posts results for Phase 2 SDX trial in idiopathic hypersomniaJun 30Trial updateserdexmethylphenidateZevra Therapeutics, Inc.